2025 is turning out to be one of the most pivotal years for pharmaceutical M&A activity in recent history.Read More

In June 2025, the government imposed anti-dumping duties on four chemicals—most of them sourced from China.Read More

As we move deeper into 2025, biosimilars are gaining unprecedented traction.Read More

When it comes to global demand, few active pharmaceutical ingredients rival Ibuprofen, a widely trusted, fast-acting NSAID used across hospitals, retail shelves, and emergency protocols.Read More

The global cosmetic industry valued at $450 billion in 2025 isn’t just expanding.Read More

The biotech and pharma industries are evolving at breakneck speed. But most professionals still lump them together—missing the nuances that define their risks, opportunities, and strategic decisions.Read More

What do Paracetamol, Metformin, and Amoxicillin have in common? They’re among the most consumed active pharmaceutical ingredients (APIs) in the worldRead More

Get a snapshot of Atorvastatin’s global DMF filings, certification types, and sourcing insights using publicly available Chemxpert data. Atorvastatin isn’t new. But it still dominates.Read More

Global drug pricing isn’t just a policy issue—it’s a business-critical variable that affects every player in the pharmaceutical value chain. FromRead More

Biosimilars are near-identical versions of approved biologics, offering similar safety, efficacy, and quality—but at a lower cost. Unlike generics, biosimilars are made from living cells and require complex development and regulatory approval.Read More